methylprednisolone has been researched along with Immunoglobulin Light-chain Amyloidosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahlis, NJ; Duggan, P; Jimenez-Zepeda, VH; Lee, H; McCulloch, S; Neri, P; Tay, J | 1 |
| Suzuki, K | 1 |
1 review(s) available for methylprednisolone and Immunoglobulin Light-chain Amyloidosis
| Article | Year |
|---|---|
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
1 other study(ies) available for methylprednisolone and Immunoglobulin Light-chain Amyloidosis
| Article | Year |
|---|---|
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Topics: Aged; Alberta; Antibodies, Monoclonal; Basement Membrane; Bortezomib; COVID-19; COVID-19 Testing; Cyclophosphamide; Dexamethasone; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Kaplan-Meier Estimate; Lenalidomide; Male; Methylprednisolone; Middle Aged; Neoplasm, Residual; Pandemics; Paraproteinemias; Precision Medicine; Retrospective Studies; SARS-CoV-2; Telemedicine | 2021 |